“中国药企的国际化进程尚处于起步阶段。展望未来，随着创新能力的持续提升，预计国内获批的创新药数量将稳步增加，市场销售额也将显著增长。未来十年，有望涌现更多年销售额突破 20 亿美元的国产重磅新药，并由此助力一批本土企业成长为具备全球竞争力的跨国制药企业。”——杨大俊博士亚盛医药共同创始人、董事长、CEO在创新药研发这片充满机遇与角逐的领域，追逐风口似乎已成为一种常态，但亦非必选项。当很多企业在不停...
Source Link“中国药企的国际化进程尚处于起步阶段。展望未来，随着创新能力的持续提升，预计国内获批的创新药数量将稳步增加，市场销售额也将显著增长。未来十年，有望涌现更多年销售额突破 20 亿美元的国产重磅新药，并由此助力一批本土企业成长为具备全球竞争力的跨国制药企业。”——杨大俊博士亚盛医药共同创始人、董事长、CEO在创新药研发这片充满机遇与角逐的领域，追逐风口似乎已成为一种常态，但亦非必选项。当很多企业在不停...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.